From Prototype to Patients: 6 Startups With Human Study Results

Why AND Biotech stands out

AND Biotech already sells four NooQ Nutrition products, but the evidence signal is the study behind Muscle Charge. In a randomized, double-blind crossover study in professional SC Bern ice-hockey players, creatine kinase was significantly lower 36 hours after the product compared with placebo.

What AND Biotech is building

NooQ Nutrition combines dietary nucleotides with established nutrients across products for vitality, muscle recovery, immune support and gut health.

The formulations use dietary nucleotides, the building blocks of DNA and RNA. Cell Vitality provides 340 mg per daily serving, Immune Shield 300 mg and Muscle Charge 1.3 g, with Muscle Charge combining nucleotides with 3 g creatine, 10 g D-ribose and magnesium per daily sachet.

Why CT Provision stands out

CT Provision's HOP model has been tested retrospectively on data from 127 patients with subarachnoid haemorrhage. A preprint reports an AUC of 0.731 for vasospasm or delayed cerebral ischaemia and 0.857 for death.

HOP runs on QMENTA, a cloud platform for medical imaging research, which handles data storage and processing without new hospital IT deployment.

What CT Provision is building

HOP combines admission brain CT images with clinical variables to estimate risks of vasospasm, delayed cerebral ischaemia and death after subarachnoid haemorrhage.

Why Nuuron stands out

Nuuron is already presenting early readouts from an ongoing patient trial of its home-based visual neurostimulation approach. An eight-patient mechanistic study also found that stimulation increased memory-related brain signals.

What Nuuron is building

The Memory Pacemaker uses precisely timed visual stimulation delivered through smart glasses to engage brain activity associated with memory formation and recall.

Nuuron's route from prototype to patients therefore runs through two evidence layers: first showing that the stimulation reaches the intended brain process, then showing that repeated home use changes outcomes that matter to people with cognitive impairment or Alzheimer's disease.

Why Equilibrium Diagnostics stands out

Equilibrium Diagnostics is built around human kidney data rather than an animal proxy. The uAPI concept has been evaluated across chronic-kidney-disease cohorts, with peer-reviewed and 2026 preprint evidence supporting urine ammonium and pH as measures of tubular function and progression risk.

That makes the evidence directly relevant to the diagnostic question: whether a simple urine measurement can add clinically useful information about a part of kidney function that current routine tests capture poorly.

What Equilibrium Diagnostics is building

Equilibrium Diagnostics is developing the AP Reader and urine Ammonium–pH Index (uAPI). The AP Reader measures urinary ammonium and pH in a single sample, and the index combines them to assess tubular kidney function and help stratify risk in chronic kidney disease.

Why Di & Care stands out

Noxxea has already been prescribed to more than 1,000 patients. In the REST-NOXXEA study, insomnia severity fell by 7.32 points and 79.3% of participants finished below the moderate-to-severe range.

That places the evidence close to the actual product and use case: a prescribed digital treatment being evaluated in people with insomnia rather than a general wellness intervention.

What Di & Care is building

Noxxea delivers a four-week digital cognitive behavioral therapy programme for chronic insomnia through a smartphone, within a physician-prescribed pathway.

Why En Carta Diagnostics stands out

En Carta Diagnostics has human-sample evidence supporting an earlier Zika application of its platform, with 98.5% reported diagnostic accuracy across 268 serum samples. Its Lyme programme is recruiting patients in Boston and has received FDA Breakthrough Device designation.

What En Carta Diagnostics is building

EC Pocket Lyme uses microneedles to sample skin interstitial fluid and a portable molecular assay to detect Borrelia near the point of need.

The molecular assay is being developed in a portable, single-use cassette that does not depend on centralized laboratory infrastructure. The format is intended for near-patient settings such as primary care and pharmacies.